Cost-Effectiveness of Vaccinating Immunocompetent ≥65 Year Olds with the 13-Valent Pneumococcal Conjugate Vaccine in England

BACKGROUND: Recently a large clinical trial showed that the use of 13-valent pneumococcal conjugate vaccine (PCV13) among immunocompetent individuals aged 65 years and over was safe and efficacious. The aim of this study was to assess the cost-effectiveness of vaccinating immunocompetent 65 year old...

Descripción completa

Detalles Bibliográficos
Autores principales: van Hoek, Albert Jan, Miller, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767406/
https://www.ncbi.nlm.nih.gov/pubmed/26914907
http://dx.doi.org/10.1371/journal.pone.0149540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767406/
https://www.ncbi.nlm.nih.gov/pubmed/26914907
http://dx.doi.org/10.1371/journal.pone.0149540

Ejemplares similares